Mitochondrial disease criteria

Background: Based on a previous prospective clinical and biochemical study, a consensus mitochondrial disease scoring system was established to facilitate the diagnosis in patients with a suspected mitochondrial disorder. Objective: To evaluate the specificity of the diagnostic system, we applied the mitochondrial disease score in 61 children with a multisystem disease and a suspected oxidative phosphorylation disorder who underwent a muscle biopsy and were consecutively diagnosed with a genetic mutation. Methods: We evaluated data of 44 children diagnosed with a disorder in oxidative phosphorylation, carrying a mutation in the mitochondrial or nuclear DNA. We compared them with 17 children who, based on the clinical and metabolic features, also had a muscle biopsy but were finally diagnosed with a nonmitochondrial multisystem disorder by further genetic analysis. Results: All children with a genetically established diagnosis of a primary oxidative phosphorylation disorder had a mitochondrial disease score above 6 (probable mitochondrial disorder), and 73% of the children had a score above 8 (definite mitochondrial disorder) at evaluation of the muscle biopsy. In the nonmitochondrial multisystem disorder group, the score was significantly lower, and no patients reached a score comparable with a definite respiratory chain disorder. Conclusions: The mitochondrial disease criteria system has a high specificity to distinguish between mitochondrial and other multisystem disorders. The method could also be applied in children with a suspected mitochondrial disorder, prior to performing a muscle biopsy.

[1]  R. Rodenburg,et al.  Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. , 2006, Clinical chemistry.

[2]  D. Thorburn,et al.  Decreased activities of mitochondrial respiratory chain complexes in non‐mitochondrial respiratory chain diseases , 2006, Developmental medicine and child neurology.

[3]  R. Artuch,et al.  Hyperlactatemia in Human Immunodeficiency Virus–Uninfected Infants Who Are Exposed to Antiretrovirals , 2004, Pediatrics.

[4]  L. Faivre,et al.  Severe lactic acidosis and acute thiamin deficiency: A report of 11 neonates with unsupplemented total parenteral nutrition , 2004, Journal of Inherited Metabolic Disease.

[5]  D. Thorburn,et al.  Mitochondrial disorders: Prevalence, myths and advances , 2004, Journal of Inherited Metabolic Disease.

[6]  J. Smeitink,et al.  Mitochondrial disorders: Clinical presentation and diagnostic dilemmas , 2003, Journal of Inherited Metabolic Disease.

[7]  E. Wirrell,et al.  Prolonged Neonatal Seizures Exacerbate Hypoxic-Ischemic Brain Damage: Correlation with Cerebral Energy Metabolism and Excitatory Amino Acid Release , 2003, Developmental Neuroscience.

[8]  R. Djaldetti,et al.  Familial infantile bilateral striatal necrosis: Clinical features and response to biotin treatment , 2002, Neurology.

[9]  N. Brahmi,et al.  Hyperlactatemia and hyperammonemia as secondary effects of valproic acid poisoning. , 2000, The American journal of emergency medicine.

[10]  A. Verbeek,et al.  A Prognostic Index as Diagnostic Strategy in Children Suspected of Mitochondriocytopathy , 2000, Neuropediatrics.

[11]  B. Echenne,et al.  Encephalopathy with calcifications of the basal ganglia in children. A reappraisal of Fahr's syndrome with respect to 14 new cases. , 1989, Neuropediatrics.

[12]  R. Lowry Early onset of Cockayne syndrome. , 1982, American journal of medical genetics.

[13]  D. Howse Metabolic responses to status epilepticus in the rat, cat, and mouse. , 1979, Canadian journal of physiology and pharmacology.

[14]  Massimo Zeviani,et al.  Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. , 2006, Cell metabolism.